Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Feb 9, 2024
- Accession no.
- 0001209191-24-003053
- Filed
- Feb 9, 2024
- Trade date
- Feb 7, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $445.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 7, 2024 | Class A Common Stock | CConversionAcquired | +10,000 | $0.00 | $0 | 801,725 | Direct | |
| Feb 7, 2024 | Class A Common Stock | GGiftDisposed | −10,000 | $0.00 | $0 | 791,725 | Direct | |
| Feb 7, 2024 | Class A Common Stock | MOption exerciseAcquired | +31,250 | $2.48 | +$77,500 | 822,975 | Direct | |
| Feb 7, 2024 | Class A Common Stock | SSaleDisposed | −48,272 | $9.22F3 | −$445,067.84 | 774,703 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 7, 2024 | Class A Common Stock | MOption exerciseDisposed | −31,250 | $0.00 | $0 | 343,750 | Direct | |
| Feb 7, 2024 | Class A Common Stock | CConversionDisposed | −10,000 | $0.00 | $0 | 6,471,496 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $9.07 to $9.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.